January 13, 2020
Dexcom’s G6 Continuous Glucose Monitoring system will soon be integrated with Livongo’s platform, thanks to a new partnership between the two diabetes-focused companies.
G6 users who are also Livongo members will be able to sync their device to the Livongo platform, which will be able to give users insights and health nudges about their behavior based on the CGM reading. The system will also be...
December 17, 2019
Dublin-based medical technology company Medtronic has acquired digital health startup Klue, a two-year-old startup which uses gesture sensing and other behavioral health metrics to determine when someone is eating. Nothing was disclosed about the terms of the deal, except that Medtronic considers it to be immaterial to 2020 earnings per share.
"Bringing Klue and their unique meal detection...
December 16, 2019
Somerville, Massachusetts-based Podimetrics has bumped its $13.4 million Series B funding round up to $16.55 thanks to a new investment from Polaris Partners.
The company, which makes a connected platform for diabetic foot ulcer detection, also announced the addition of five new names to advisory board: Dr. Kenneth Kizer, former Veterans Affairs undersecretary for health; Dr. Ronald Geraty, a...
December 10, 2019
Sanofi announced a major strategy shift today that will end the pharma’s diabetes and cardiovascular R&D efforts in favor of a reinvigorated focus on growing its immunology and vaccine businesses.
Among the fallout of this new game plan is Onduo, the pharma’s diabetes management joint venture with Verily that the two companies invested $500 million into back in 2016, according to the company’...
December 3, 2019
Dexcom continuous glucose monitor users and their caregivers found themselves in the dark this weekend when a key monitoring feature ceased to function with little to no warning.
The feature, called Dexcom Follow, transmits an alert when a CGM user’s blood sugar reaches a dangerous level and is often used by parents monitoring their children’s condition. When unexpected issues brought down the...
November 21, 2019
Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday.
To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. The two will also be...
November 20, 2019
The US Department of Veterans Affairs recently announced a regional rollout that it will make a connected device for diabetic foot ulcer detection available to veterans across the country as of December 1.
The platform, developed by Somerville, Massachusetts-based Podimetrics, is already being used at 15 of the department’s medical centers, and according to the VA will also be included in an...
November 15, 2019
Livongo is touting new data regarding the efficacy of its device-and-coaching disease management platform, this time among those using its Livongo for Hypertension and Livongo for Diabetes products together.
The results, which are set to be formally presented this weekend at the American Heart Association Scientific Sessions 2019, identified significant decreases in hypertensive blood pressure as...
November 14, 2019
Digital chronic care platform Omada is deepening its relationship with Blue Cross and Blue Shield of Minnesota (Blue Cross), inking a new deal that provides the insurer’s commercial plan members access to the startup’s Type 2 diabetes care platform.
As part of yesterday’s news, Blue Cross also announced it would be making a strategic investment in Omada; however, the actual value of this...
November 11, 2019
Ninety-eight percent of veterans with Type 2 diabetes enrolled in Virta’s digital diabetes management program reduced or controlled their estimated HbA1c level after 90 days, according to new results from a pilot conducted by the U.S. Department of Veterans Affairs and Virta Health.
The pilot, which included a total of 104 patients, found that 84% of patients enrolled achieved an estimated HbA1c...